Candel Therapeutics Inc (NASDAQ:CADL) shares, rose in value on Thursday, December 12, with the stock price up by 26.45% to the previous day’s close as strong demand from buyers drove the stock to $9.80.
Actively observing the price movement in the last trading, the stock closed the session at $7.75, falling within a range of $7.9092 and $10.82. The value of beta (5-year monthly) was -0.874. Referring to stock’s 52-week performance, its high was $14.60, and the low was $1.00. On the whole, CADL has fluctuated by 119.24% over the past month.
With the market capitalization of Candel Therapeutics Inc currently standing at about $318.27 million, investors are eagerly awaiting this quarter’s results, scheduled for in January.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CADL’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of CADL currently trading nearly 97.83% and 83.20% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 81.24, while the 7-day volatility ratio is showing 42.17% which for the 30-day chart, stands at 18.87%. Furthermore, Candel Therapeutics Inc (CADL)’s beta value is -0.94, and its average true range (ATR) is 1.30.
A comparison of Candel Therapeutics Inc (CADL) with its peers suggests the former has fared considerably weaker in the market. CADL showed an intraday change of 26.45% in last session, and over the past year, it grew by 870.30%%.
Data on historical trading for Candel Therapeutics Inc (NASDAQ:CADL) indicates that the trading volumes over the past 10 days have averaged 10.67 and over the past 3 months, they’ve averaged 1.95 million. According to company’s latest data on outstanding shares, there are 32.13 million shares outstanding.
Nearly 37.53% of Candel Therapeutics Inc’s shares belong to company insiders and institutional investors own 14.78% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.78 million shares as on 2024-10-31, resulting in a short ratio of 7.72. According to the data, the short interest in Candel Therapeutics Inc (CADL) stood at 806.00 of shares outstanding as of 2024-10-31; the number of short shares registered in 2024-09-30 reached 1.59 million. The stock has risen by 566.67% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CADL stock heading into the next quarter.
